Finerenone and its role in diabetic kidney disease state of the art

Diabetic kidney disease represents the leading cause of endstage kidney disease and its presence directly impacts cardiovascular risk and mortality in individuals with diabetes mellitus. Since albuminuria is the main marker of DKD, its reduction has been established in recent years as one of the the...

Full description

Saved in:
Bibliographic Details
Published inArchivos de medicina Vol. 18; no. 1
Main Authors Navas Torrejano, Diana, Aguilar Salcedo, Nataly, Raad, María, Uparella Gulfo, Isabella, Rico Fontalvo, Jorge Eduardo, Alfaro, Mercedes, Abuabara Franco, Emilio, Cardona Blanco, María, Daza Arnedo, Rodrigo
Format Journal Article
LanguageEnglish
Published 2022
Subjects
Diabetic kidney disease
Finerenone
Mineralocorticoid antagonist
Online AccessGet full text

Cover

More Information
Summary:Diabetic kidney disease represents the leading cause of endstage kidney disease and its presence directly impacts cardiovascular risk and mortality in individuals with diabetes mellitus. Since albuminuria is the main marker of DKD, its reduction has been established in recent years as one of the therapeutic objectivesto impact the evolution of the disease. Finerenone, a mineralocorticoid receptor antagonist, has been described in several recent studies as a drug whose mechanism of action could contribute to reducing the progression of DKD, reducing the progression of eGFR and albuminuria with an adequate profile of safety in patients with all stages of kidney disease.
ISSN:1698-9465
1698-9465